First vaccine approved by FDA to prevent serogroup B Meningococcal disease.

On October 29, 2014, the U.S. Food and Drug Administration announced the approval of Trumenba, the first vaccine licensed in the United States to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age.  Of the 500 cases of meningococcal disease reported in the United States in 2012, 160 were caused by serogroup B, according to the U.S. Centers for Disease Control and Prevention.

While we are still awaiting an official recommendation of the ACIP and incorporation into the existing immunization schedule, prescribing information shows that the new vaccine is to be administered as a 3-dose series at months 0, 2 and 6 in the 10 through 25 year old age group.

Trumenba is manufactured by Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc., Philadelphia, Pennsylvania.